Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immix Biopharma, Inc. - Common Stock (NQ: IMMX )

1.870 +0.060 (+3.31%)
Streaming Delayed Price Updated: 11:39 AM EDT, Sep 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 18,176
Open 1.870
Bid (Size) 1.860 (1)
Ask (Size) 1.870 (5)
Prev. Close 1.810
Today's Range 1.840 - 1.880
52wk Range 1.750 - 7.750
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
From Immix Biopharma, Inc.
Via GlobeNewswire
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024
IMMX stock results show that Immix Biopharma beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
-69.14%
-69.14%
1 Month
+0.53%
+0.53%
3 Month
-10.10%
-10.10%
6 Month
-34.16%
-34.16%
1 Year
-32.25%
-32.25%

More News

Read More
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
From Immix Biopharma, Inc.
Via GlobeNewswire
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024
Via InvestorPlace
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma on Track to Dose NXC-201 Patients in United States
From Immix Biopharma, Inc.
Via GlobeNewswire
IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023
Via InvestorPlace
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
From Immix Biopharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Immix Biopharma Inc. (NASDAQ: IMMX) Closes on $15M Public Offering
Via Investor Brand Network
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces Proposed Public Offering of Common Stock
From Immix Biopharma, Inc.
Via GlobeNewswire
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
From Immix Biopharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.